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Despite extensive research, many details about the structure and functions of hepatitis C virus
(HCV) glycoproteins E1 and E2 are not fully understood, and their crystal structure remains to be
determined. We applied linker-scanning mutagenesis to generate a panel of 34 mutants, each
containing an insertion of 5 aa at a random position within the E1E2 sequence. The mutated
glycoproteins were analysed by using a range of assays to identify regions critical for maintaining
protein conformation, E1E2 complex assembly, CD81 receptor binding, membrane fusion and
infectivity. The results, while supporting previously published data, provide several interesting new
findings. Firstly, insertion at amino acid 587 or 596 reduced E1E2 heterodimerization without
affecting reactivity with some conformation-sensitive mAbs or with CD81, thus implicating these
residues in glycoprotein assembly. Secondly, insertions within a conserved region of E2, between
amino acid residues 611 and 631, severely disrupted protein conformation and abrogated binding
of all conformation-sensitive antibodies, suggesting that the structural integrity of this region is
critical for the correct folding of E2. Thirdly, an insertion at Leu-682 specifically affected
membrane fusion, providing direct evidence that the membrane-proximal ‘stem’ of E2 is involved in
the fusion mechanism. Overall, our results show that the HCV glycoproteins generally do not
tolerate insertions and that there are a very limited number of sites that can be changed without
dramatic loss of function. Nevertheless, we identified two E2 insertion mutants, at amino acid
residues 408 and 577, that were infectious in the murine leukemia virus-based HCV
pseudoparticle system.
INTRODUCTION
Hepatitis C virus (HCV) is an enveloped, positive-sense RNA
virus belonging to the genus Hepacivirus in the family
Flaviviridae. The envelope glycoproteins E1 and E2 are
present on the surface of the virus particle and are major
players during infection of host cells. Both are type 1
transmembrane proteins containing a highly glycosylated N-
terminal ectodomain and a C-terminal transmembrane
domain that anchors them to the membranes of the
endoplasmic reticulum (ER) (Brass et al., 2006; Helle &
Dubuisson, 2008). E1 and E2 assemble in the ER as a non-
covalent heterodimer,which wasthought tobe thefunctional
complex responsible for host cell attachment and entry
(Bartosch et al., 2003b; Dubuisson, 2007), but it has recently
been shown that glycoproteins in the envelope of infectious
virions form large covalent complexes that are stabilized by
disulphide bridges (Vieyres et al., 2010). Entry involves
multiple interactions of viral particles with a set of co-
receptors required at sequential entry steps of attachment,
binding, endocytosis and fusion (Benedicto et al., 2008; Helle
& Dubuisson, 2008; Ploss etal., 2009). The tetraspanin CD81,
scavenger receptor class B type I, and the tight junction
proteins claudin-1 and occludin have all been identified as
being essential for virus entry, but direct binding of the E1E2
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(Cocquerel et al., 2003). Owing to the association of HCV
particles with very low density lipoproteins during virus
assembly and secretion, lipoprotein receptors are also
important entry factors (Burlone & Budkowska, 2009).
Various structural and functional features of the E1E2
heterodimerhave been described, includingresidues involved
in heterodimerization (Ciczora et al., 2005; Cocquerel et al.,
1998, 2000; Drummer & Poumbourios, 2004; Michalak
et al., 1997; Op De Beeck et al., 2000; Patel et al., 2001; Selby
et al., 1994), CD81-receptor binding (Drummer et al., 2006;
Owsianka et al., 2006; Rothwangl et al., 2008) and the ER
retention signal (Cocquerel et al., 1998). Fusion mediated by
HCV glycoproteins is pH dependent and probably occurs
after endocytosis in early endosomes (Blanchard et al., 2006;
Meertens et al., 2006; Tscherne et al., 2006). The similarity of
the genomic organization of HCV to other members of the
family Flaviviridae suggests that E2 is a class II fusion protein,
with a candidate fusion loop at amino acid residues 502–520
(Krey et al., 2010). However, several other hydrophobic
domains within E1 andE2 have been investigated aspotential
fusion peptides (Lavillette et al., 2007; Perez-Berna ´ et al.,
2006; Russell et al., 2009; Spadaccini et al., 2010). It is still
unclear which of the two partners is the fusion protein, and
how the heterodimer mediates membrane fusion.
To fulfil such a multitude of biological functions, E1 and
E2 must contain different segments with distinct prop-
erties. In the absence of a high-resolution structure,
mutational analysis can provide valuable insights into the
relationship between structure and function. In this study
we constructed a panel of mutants with insertions
randomly distributed throughout E1 and E2, and subjected
them to a comprehensive functional analysis by using a
hierarchy of assays – from protein folding to infectivity – in
order to identify and delineate functional domains.
RESULTS AND DISCUSSION
Construction and expression of E1 and E2
insertion mutants
Linker-scanning mutagenesis was employed to generate a
library of 5 aa insertions in E1 and E2. Briefly, an in vitro
transposition reaction was used to introduce a 15 bp
insertion at random into genotype 1a strain H77c E1E2
cDNA, resulting in a single 5 aa insertion in the protein.
Fifty insertion mutants were isolated, of which 35 encoded
‘read-through’ mutations while 15 contained premature
stop codons. The read-through insertions were distributed
fairly evenly, with 11 located in E1, one in the E1 signal
peptide and 23 in E2 (Fig. 1). The identity of the amino
acids encoded by the insertions is given in Table 1. Mutants
were numbered according to the amino acid position of the
viral polyprotein immediately N-terminal to the insertion
site. Natural glycosylation sites were preserved in all
mutants except in577, which lacked the glycosylation site
at Asn-576 (Table 1). We selected the 34 read-through
mutants and compared their properties with those of wild-
type (WT) E1E2 across a range of functions, from the
fundamental characteristics of correct folding and hetero-
dimerization to the higher level functions of fusion and
infectivity. The results of all these experiments are
summarized and correlated in Table 2. As an extra positive
control, in addition to WT, we included in178, which had
an insert in the E1 signal peptide and therefore expressed
WT E1E2 glycoprotein. All experiments included a negative
control that lacked E1 and E2 glycoproteins, and, in
addition to this no-glycoprotein control, as a second E2-
negative control we used the mutant in515-STOP, which
has a premature stop codon at amino acid 515 and
therefore expresses a truncated E2 protein.
To check for stable expression of mutated glycoproteins,
lysates of HEK-293T cells transiently transfected with WT
and mutant E1E2 were tested by Galanthus nivalis
agglutinin (GNA) ELISA for reactivity to anti-E1 and
anti-E2 mAbs that recognize linear epitopes. Upon serial
dilution of lysates we saw a reasonably constant relation-
ship between the dilution and the signal, showing that the
assay was not saturated and that the signal was dependent
on the concentration of glycoprotein present in the lysate
(not shown). All mutants gave a signal that was at least
50% of the WT signal observed with E1 mAbs H-111 and/
or AP21.010. Similarly, all mutants (except for the negative
control mutant in515-STOP) gave a signal that was at least
90% that of WT with mAb AP33, and at least 65% that of
WT with mAb ALP98 (Table 2). Given that all the
transiently expressed mutated glycoproteins were of similar
concentration and stability in crude cell lysates, the relative
Fig. 1. Schematic representation of insertions
in HCV E1 and E2 proteins. Arrows indicate
the position of each 5 aa insertion. Numbers
correspond to the amino acid immediately
preceding the insertion in the HCV polyprotein.
The insertion at amino acid position 515
encodes a stop codon, resulting in a truncated
E2 protein. Also shown are the E1 signal
peptide (SP), and the transmembrane domains
(TMD).
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analysed in the assays described below.
Antigenic analysis of mutated E1E2 reveals a
strong folding determinant in the E2 glycoprotein
To analyse the influence of insertions on protein folding,
lysates of HEK-293T cells transiently transfected with WT
and mutant E1E2 were tested by GNA ELISA for reactivity
with conformation-sensitive murine anti-E2 mAbs H35,
H48 and H53, and human anti-E2 mAbs CBH-4B, CBH-
4D, CBH-4G, CBH-5 and CBH-7. The concentration of
each lysate was normalized on the basis of reactivity with
mAbs AP33 and ALP98. Several mutants were clearly much
less reactive with the conformation-sensitive mAbs than
WT. To stringently define the mutations that had the
greatest effect, the data were analysed statistically and those
where P,0.01 were considered to be significant.
The most striking result was that four consecutive mutants
in the region between amino acid residues 611 and 631
were not recognized by any of the conformation-sensitive
mAbs (Fig. 2 and Table 2), which shows that these mutants
were misfolded. This region is highly conserved in different
HCV genotypes and has been implicated in dimerization
(Yagnik et al., 2000), CD81 binding (Roccasecca et al.,
2003; Rothwangl et al., 2008), membrane fusion (Lavillette
et al., 2007), binding of conformation-sensitive mAbs and
infectivity (Iacob et al., 2008; Rothwangl et al., 2008). A
new model of the tertiary structure of E2 assigns amino
acid residues 581–651 to a distinct structural domain
(DIII) stabilized by two long-range disulphide bonds,
C597–C620 and C607–C644 (Krey et al., 2010, reproduced
in Fig. 6). We propose that the region bounded by these
disulphide bonds comprises a critical folding determinant
whose structure is essential for the correct folding and
functioning of E2.
Likewise, there was a highly significant reduction in
binding (P,0.01) of all eight mAbs with mutants in540
and in549 (Fig. 2 and Table 2), showing that this region,
which forms part of the central DI domain in the model
(Fig. 6), is also essential for correct protein folding. It has
been observed that mutation of the glycosylation site at
N540 consistently reduces the affinity of various neutral-
izing antibodies, including CBH-5, CBH-7 and H48 (Helle
et al., 2007; Owsianka et al., 2008), suggesting that absence
of the glycan induces a local change in conformation. It is
not surprising, therefore, that an insertion at this position
has a similar effect.
In contrast, mutations in two other regions, amino acid
residues 531–534 and 587–597, had a more selective effect.
Insertions in531 and in533 severely reduced the binding of
H35, H48 and CBH-5, but had little or no effect on the
binding of the other five mAbs. Insertion in587 severely
reduced the binding of CBH-4B, -4D and -4G and
moderately that of H35, CBH-5 and CBH-7, but had no
effect on H48 and H53. Similarly, in596 severely reduced
the binding of CBH-4B, -4D and -4G, and moderately that
of CBH-7, but had no effect on the other four mAbs (Fig. 2
and Table 2). Therefore, these insertions do not cause E2 to
misfold, but probably disrupt antibody epitopes or else
induce a very local conformational change that affects the
binding of some mAbs but not others. The mAbs used in
this study have been fairly well characterized, but our
knowledge of the residues that contribute to their
conformational epitopes is incomplete. The five human
Table 1. Amino acid sequence of insertions
Inserted amino acids are shown in italics. All N-linked glycosylation
sites are in boldface type.
Mutant* Insertion context
in178 SFSIFL FKHFL LALL
in194 SAYQV FKHQV RNSS
in197D QVRNS CLNNS SGLY
in203 GLYHV FKHHV TNDC
in218 EAAD VFKHD AILHT
in231 PCVR CLNIR EGNAS
in253 RDGKL FKHK LPTTQ
in263 RRHID CLNID LLVGS
in324 DMMM FKQMM NWSP
in341 LLRIP LFKHP QAIMD
in343 RIPQA CLNKA IMDMI
in352 IAGAH CLNTH WGVL
in408 PGAK LFKHK QNIQL
in413 QNIQL MFKQL INTNGS
in422 GSWHI MFKHI NSTAL
in424D WHINS CLNNS TALNC
in456 CPERL VFKQL ASCRR
in515 TPSPVV STOP
in531 SWGA MFKHA NDTD
in533D GAND CLNND TDVFV
in540D FVLN CLNIN NTRPP
in549 GNW CLNNW FGCT
in573 VIGG CLNRG VGNN
in577d VGNN MFKHN TLLCP
in587 DCFR CLNIR KHPEA
in596 TYSR CLNTR CGSG
in611 MVDY LFKHY PYRL
in614 YPYR LFKHR LWHY
in620 HYPC CLNTC TINYT
in630 IFKVR CLNIR MYVGG
in682 SFTTL LFKHL PALS
in692 LIHL LFKHL HQNIV
in707 GVGS MFKQS SIASW
in726 LFLLL FKHLL ADARV
in732 ARVC CLNICS CLWM
in734 VCSC CLNTC LWMM
*Mutants are numbered according to the amino acid position
immediately N-terminal of the insertion site.
DFor mutants in197 in424, in533 and in540 the glycosylation motif is
reconstituted at the end of the insertion, as underlined.
dMutant in577 has lost glycosylation site Asn-576.
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Mutant E1E2 expression* E2 folding (conformation-sensitive mAb binding*) E1E2 hetero-
dimerizationD
CD81
binding*
Fusiond HCVpp
incorporationD
HCVpp
infectivity§
H111 AP21.010
binding
AP33 ALP98
binding
H35/H48 H53 CBH-4B/4D/4G CBH-5 CBH-7
in178 +++ +++ +++ +++ +++ +++ +++ +++ +++ 85% +++ 70%
in194 ++ +++ +++ +++ +++ +++ +++ ? +++ 61% ? 7%
in197 +++ +++ +++ +++ +++ +++ +++ ? +++ 7% ? 2
in203 ++ +++ +++ +++ +++ +++ +++ ? +++ 2 ? 2
in218 +++ +++ +++ +++ +++ +++ +++ +++ +++ 2 + 2
in231 +++ +++ +++ +++ +++ ++ +++ +++ +++ 2 +++ 2
in253 +++ +++ +++ +++ +++ +++ +++ +++ +++ 17% +++ 3%
in263 +++ +++ +++ +++ +++ +++ +++ +++ +++ 2 + 2
in324 +++ +++ +++ +++ +++ +++ +++ +++ +++ 22 2
in341 +++ +++ +++ +++ +++ ++ +++ +++ +++ 2 +++ 2
in343 +++ +++ +++ +++ +++ ++ +++ +++ ++ 42% ++ 2
in352 ++ +++ +++ +++ +++ +++ +++ +++ +++ 35% +++ 2
in408 +++ +++ +++ +++ +++ +++ +++ +++ +++ 159% +++ 20%
in413 +++ +++ +++ +++ +++ +++ +++ +++ +++ 7% ++ 2
in422 +++ +++ +++ +++ +++ ++ +++ +++ + 11% +++ 2
in424 +++ +++ +++ +++ +++ +++ +++ +++ + 2 +++ 2
in456 +++ +++ +++ +++ +++ +++ +++ +++ +++ 9% 22
in515 STOP +++ + 22 2 2 2 2 22 2 2
in531 +++ +++ + +++ ++ 2 +++ +++ + 2 +++ 2
in533 +++ +++ + +++ +++ 2 +++ +++ + 2 +++ 2
in540 +++ +++ ++ + + 22 ++ + 22 2
in549 +++ +++ ++ 22 2 2 ++ + 22 2
in573 +++ +++ +++ +++ +++ +++ +++ +++ +++ 7% ++ 2
in577 +++ +++ +++ +++ +++ +++ +++ ++ +++ 130% +++ 13%
in587 +++ +++ +++ +++ 2 + ++ + +++ 22 2
in596 +++ +++ +++ +++ + +++ ++ + ++ 22 2
in611 +++ +++ 22 2 2 2 +++ + 22 2
in614 +++ +++ + + 22 2 +++ + 2 +++ 2
in620 +++ +++ 2 + 22 2 +++ + 22 2
in630 +++ +++ + 22 2 2 +++ + 22 2
in682 +++ +++ +++ +++ +++ +++ +++ +++ +++ 2 +++ 2
in692 +++ +++ +++ +++ +++ +++ +++ 2 +++ 22 2
in707 +++ +++ +++ +++ +++ +++ +++ 2 +++ 22 2
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2mAbs map to three distinct domains: CBH-4B, -4D and
-4G to domain A, CBH-5 to domain B and CBH-7 to
domain C (Hadlock et al., 2000; Keck et al., 2004a).
Domain A mAbs are non-neutralizing, whereas domain B
and C mAbs inhibit E2–CD81 binding and neutralize
infectivity (Keck et al., 2004a; Owsianka et al., 2008).
Mouse mAbs H35 and H48 are neutralizing, while H53 is
non-neutralizing (Bartosch et al., 2003a; Cocquerel et al.,
1998; Dubuisson et al., 1994). The neutralizing mAbs H35,
H48 and CBH-5 have a similar footprint, and Gly-530 is a
critical binding residue for all three antibodies (Keck et al.,
2008; Owsianka et al., 2006, 2008). This suggests that
insertions in531 and in533 directly disrupt an important
component of their common epitope, with little impact on
E2 conformation. On the other hand, insertions in587 and
in596 affect the binding of mAbs that recognize different
epitopes, so they may induce a local conformational change
that does not alter the overall folding of E2.
Influence of insertions on E1E2 heterodimer
formation
We investigated the ability of mutated E1E2 that was
transiently expressed in HEK-293T cells to assemble into
non-covalent heterodimers. The proteins were immuno-
precipitated with rabbit polyclonal anti-E2 serum R646,
separated by using SDS-PAGE under reducing and non-
reducing conditions, and detected by immunoblotting. The
WT heterodimer consisted of E2, which migrated pre-
dominantly as a single band, associated non-covalently
with different glycoforms of E1 (Fig. 3). Most of the
mutants were co-precipitated by anti-E2 serum R646,
although some variation in migration and glycosylation
patterns was observed.
Analysis on non-reducing gels showed that E2 mutants
in540, in549, in587, in596, in707 and in726 yielded lower
levels of co-precipitated E1, which indicated impaired
E1E2 heterodimer formation (Fig. 3b and Table 2). In E2
mutant in692 (and also in the truncated in515-STOP
mutant), we observed reduced immunoprecipitation of E2
and no detectable co-precipitation of E1. The apparent
lack of E1 in the case of mutants in197 and in203 is caused
by these insertions disrupting the epitope (aa 197–207) of
mAb A4, which was used for detection, and should not be
interpreted as a lack of heterodimerization. The only E1
mutant that showed a reduced level of heterodimerization
is in194, but, because the insertion is very close to the A4
epitope, this result cannot be interpreted with certainty.
The reduced heterodimerization observed for mutants in540
and in549 is probably a consequence of these mutants being
misfolded, as discussed above. Mutants in587, in596, in692,
in707 and in726 are correctly folded, although in587 and
in596 may induce a local conformational change that does
not impact on the overall folding of E2. These mutants
therefore indicate two regions of E2 that are involved in
heterodimerization: amino acids 587–597 and 692–727. The
latter region spans the membrane-proximal heptad repeat
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previous work, which shows that formation of a non-
covalent heterodimer depends on interaction between the
transmembrane domains of both E1 (aa 352–383) and E2
(aa 718–746) (reviewed by Lavie et al., 2007), and that
residues in the conserved hydrophobic membrane-proximal
heptad repeat region of E2 (aa 675–699) are also required
(Drummer & Poumbourios, 2004). The region represented
by mutants in587 and in596 is located in domain DIII of the
modelofE2(Kreyetal.,2010,Fig.6),andcouldformpartof
the interface with E1 or contribute to stabilizing the
complex. In summary, our results confirm the role of the
Fig. 2. Folding analysis of mutated E1E2 using conformation-sensitive mAbs. WT and mutated E1E2 glycoproteins (numbered
as in Fig. 1) in lysates of transfected HEK-293T cells, normalized for reactivity with mAbs AP33 and ALP98, were captured by
GNA and probed with (a) mouse anti-E2 mAbs H35, H48 and H53; (b) human anti-E2 mAbs CBH-4B, -4D and
-4G; and (c) CBH-5 and CBH-7. The reactivity of each mutant is presented as a percentage of the signal for WT, after
subtracting the signal obtained with mock-transfected cell lysate. Values shown are the means and SD of three independent
assays. **, Values that differ significantly from WT (P,0.01).
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2254 Journal of General Virology 92transmembrane domain and the membrane-proximal
hydrophobic region of E2 in heterodimer formation, and
also identify another region of E2 (aa 587–597) that may be
involved in complex assembly.
CD81 binding properties of mutated E1E2
The mutants were tested for their ability to bind CD81, an
essential receptor for virus entry into target cells (Pileri
et al., 1998). All mutants with insertions in E1 bound CD81
with approximately WT efficiency, whereas a significant
decrease in CD81 binding was observed with several E2
mutants (Fig. 4 and Table 2). A 40–55% reduction in
binding was seen with mutants in540 and in549, while all
mutants in the region between amino acid residues 611 and
631 resulted in a 70–80% reduction of CD81 binding. This
is almost certainly a consequence of protein misfolding
caused by these insertions, as described above, rather than a
direct effect. The greatest reduction (75–85%) in CD81
binding was observed for mutants in422, in424, in531 and
in533. These mutants are correctly folded, since they are
recognized by most of the conformation-sensitive mAbs
(Fig. 2 and Table 2), and therefore we conclude that these
four insertions directly affect the CD81-binding site.
Several non-contiguous amino acid residues of E2 have
been identified as being important for CD81 receptor
binding: Trp-420 and amino acid residues 436–443, 527–
535 and 613–618 (Drummer et al., 2006; Owsianka et al.,
2006; Roccasecca et al., 2003; Rothwangl et al., 2008),
indicating that the binding site is conformation-sensitive
and is dependent upon correct E2 folding. Our study shows
that mutations in531 and in533 disrupt the binding both of
soluble CD81 and of neutralizing antibodies H35, H48 and
CBH-5 (Table 2). These mutations are likely to interfere
directly with the accessibility of Trp-529, Gly-530 and Asp-
535, which are critical CD81-binding residues. Similarly,
the CD81-binding defect of mutants in422 and in424 might
result from the proximity of these inserts to Trp-420. These
four mutations are all located in close proximity to each
other on domain DI (Fig. 6) (Krey et al., 2010),
highlighting the importance of this domain for receptor
binding and virus neutralization.
Insertions in E1 and E2 have a major influence on
HCV pseudo-particle infectivity
Having established that a number of insertions had multiple
effects on both the structure and function of E1E2, we
related these effects to infectivity by generating recombinant
HCV pseudo-particles (HCVpp) bearing WT or mutated
glycoproteins and testing them for infectivity of Huh-7 cells.
Most of the insertions in both E1 and E2 resulted in a
dramatic decrease or a complete loss of infectivity (Fig. 5b
and Table 2). Only four mutants maintained clearly
demonstrable levels of cell entry, although all were
significantly lower than WT: in194 (7%), in253 (3%),
in408 (20%) and in577 (13%). Only the control mutant
in178, with an insertion outside the glycoprotein sequence,
maintained normal infectivity (70% of WT), in keeping
with its WT characteristics in all other assays.
To assess whether the lack of infectivity could be explained
by impaired incorporation of glycoproteins, sucrose-
cushion-concentrated HCVpp were immunoprecipitated
with anti-E2 serum R646 and analysed by using non-
reducing SDS-PAGE followed by immunoblotting for E1,
E2 and murine leukemia virus (MLV) Gag protein
(Fig. 5c). Significant differences in E1E2 incorporation
levels were found in approximately half of the mutant
Fig. 3. Heterodimerization of mutated E1E2. WT and mutated E1E2 glycoproteins (numbered as in Fig. 1) in lysates of
transfected HEK-293T cells were immunoprecipitated with anti-E2 serum R646, resolved by (a) reducing and (b) non-reducing
SDS-PAGE, and analysed by immunoblotting with anti-E2 mAbs (AP33 and ALP98) and anti-E1 mAb A4. Bands
corresponding to different glycoforms of E1 (E1-2G, -3G and -4G) are indicated. No env, Mock-transfected control cells. (c) b-
Actin immunodetection to check the protein concentration of cell lysates.
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were seen in mutants in218, in263 and in324, and very low
levels of one or both glycoproteins in mutants in456, in540,
in549, in587, in596, in611, in620, in630, in692, in707, in732,
in734 and the truncated control in515-STOP. As previously,
the apparent lack of E1 in the case of mutants in194, in197
and in203 is caused by these insertions disrupting the
epitope of mAb A4, and should not be interpreted as a lack
of incorporation. All of the misfolded mutants produced
defective HCVpp except for in614, which, intriguingly,
incorporated the non-covalent heterodimer at WT levels.
Fusion competence of mutated E1E2
We reasoned that non-infectious mutants that incorporated
normal levels of glycoproteins might have a reduced
membrane fusion capability. To perform a cell-based fusion
assay, HEK-293T donor cells were co-transfected with
plasmids encoding E1 and E2 glycoproteins, together with
a luciferase reporter gene under the control of the human
immunodeficiency virus (HIV)-1 LTR. Donor cells were co-
cultivated with Huh7-J6 indicator cells expressing HIV-1
transcription transactivator protein (Tat), and fusion was
induced by lowering the pH to 5. Under these conditions
donor cells bearing WT E1E2 gave a robust signal of 10
5
relative luminescence units (RLU), while donor cells lacking
HCV glycoproteins gave a signal of ,10
3 RLU. To further
validate the assay, donor cells expressing WT E1E2 and
luciferase reporter were combined with indicator cells
devoid of Tat transactivator, and this combination also
resulted in a signal of ,10
3 RLU.
We found a clear correlation between the infectivity profile
of the mutants and their ability to mediate cell fusion (Fig.
5a, b). Most of the mutants were severely impaired or
unable to mediate fusion, but several retained a significant
proportion of WT fusogenic activity, specifically E1
mutants in194 (61%), in253 (17%), in343 (42%) and
in352 (35%), and E2 mutants in408 (159%) and in577
(130%). Only those mutants (in194, in408 and in577) that
had levels of fusogenic activity close to or greater than WT
retained moderate (7% to 20%) HCVpp infectivity (Table
2). This may be because both assays depend on the
expression of functional glycoproteins on the plasma
membrane of HEK cells. All three infectious mutants have
inserts in highly variable regions: in194 is at the very N
terminus of E1, in408 is in the first hypervariable region
(HVR1) of E2 and in577 is in the intergenotypic variable
region (igVR) of E2. HVR1 is dispensable for HCV
infection but viruses lacking this region or carrying an
insertion in it have been shown to be less infectious
(Bankwitz et al., 2010; Forns et al., 2000; Wakita et al.,
2005). The igVR is extremely variable in sequence and also
in length (10–15 aa, depending on genotype), but all
isolates contain a single conserved N-linked glycosylation
site at approximately amino acid position 576 (Humphreys
et al., 2009; McCaffrey et al., 2007). Interestingly, the igVR
is predicted to function as an inter-domain hinge region,
which allows the molecule to flex and go through the large
conformational change that is necessary to mediate fusion
(Krey et al., 2010). Our data suggest that this region is so
plastic that it can tolerate an increase in length from 11 to
16 aa and also the loss of an N-linked glycan (the
glycosylation site is disrupted in the in577 mutant). This
is in keeping with previous work, which showed that
HCVpp lacking this glycosylation site retained infectivity
(Goffard et al., 2005; Helle et al., 2007).
Fusion occurs upon endocytosis in early endosomes and
requires an acidic pH, which induces a conformational
Fig. 4. CD81 binding of mutated E1E2. Immobilized glutathione S-transferase (GST)–CD81 large extracellular loop (LEL) was
used to capture WT and mutated E1E2 glycoproteins (numbered as in Fig. 1) from lysates of transfected HEK-293T cells. The
concentration of lysate was normalized for reactivity with AP33 and ALP98 mAbs in a GNA ELISA. CD81-bound E2 was
detected by using anti-E2 serum R646. Binding of each mutant is presented as a percentage of the signal for WT, after
subtracting the signal obtained with mock-transfected cell lysate. Values shown are the means and SD of assays performed in
triplicate. Consistent data were obtained in two or more independent experiments. Asterisks indicate values that differ
significantly from WT: **, P,0.01; *, P50.04.
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& Dubuisson, 2008). Mutagenesis of conserved residues in
putative fusion-active regions has identified three regions
that may be functionally important: amino acid residues
259–286 in E1, and 416–430 and 600–620 in E2 (Drummer
et al., 2007; Lavillette et al., 2007; Russell et al., 2009), and
Fig. 5. Membrane fusion activity and HCVpp infectivity of mutated E1E2. (a) HEK-293T cells expressing WT or mutated E1E2
glycoproteins (numbered as in Fig. 1), together with luciferase under the control of the inducible HIV-1 LTR promoter, were co-
cultivated with Huh7-J6 indicator cells expressing HIV-1 Tat protein. Fusion was induced by low-pH treatment and 24 h later
luminescence was measured. The value for each mutant is expressed as a percentage of the signal for WT, after subtracting the
signal obtained with donor cells devoid of HCV glycoproteins. Values shown are the means and SD of assays performed in
triplicate. Consistent data were obtained in two or more independent experiments. (b, c) Pseudoparticles were generated that
incorporated WT and mutated E1E2 glycoproteins (numbered as in Fig. 1), or no envelope glycoproteins (No env). (b) The
pseudoparticles were used to infect Huh-7 cells, and infectivity was measured after 4 days by using a GFP reporter assay. The
infectivity of each mutant is expressed as a percentage of the signal for WT, after subtracting the infectivity of the no-envelope
control. Values shown are the means and SD of assays performed in triplicate. Similar results were obtained by using a luciferase
reporter. (c) Concentrated pseudoparticles were immunoprecipitated with polyclonal anti-E2 serum R646, resolved by non-
reducing SDS-PAGE and analysed by immunoblotting for E2 (mAbs AP33 and ALP98), E1 (mAb A4) and MLV capsid (CRL-
1912).
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comprises amino acid residues 502–520 in E2 (Krey et al.,
2010). Several of our mutants (in263, in422, in424, in611,
in614 and in620) have insertions that disrupt one of these
regions, and they are all negative for membrane fusion.
However, each of them is deficient in at least one other
function: mutant in263 does not incorporate normal levels
of E1 into HCVpp, and is therefore unlikely to display
normal levels of E1 on the plasma membrane of transfected
HEK cells; mutants in422 and in424 do not bind CD81;
while mutants in611, in614 and in620 are misfolded. In each
case the lack of fusion is very likely to be an indirect effect.
Similarly, the lack of fusogenic activity in most of the other
mutants can be ascribed to a defect in another function.
However, mutants in231, in341 and in682 have WT
characteristics in every assay other than fusion and
infectivity, and therefore these insertions may be having a
direct effect on the mechanism of membrane fusion. Mutant
in682 is particularly interesting because this insertion
disrupts the conserved hydrophobic heptad-repeat region
in the flexible, membrane-proximal ‘stem’ of E2 (Fig. 6). By
analogy with the well-characterized class I fusion proteins of
influenza and HIV-1, the stem region of flavivirus class II
fusion proteins is proposed to play a key role in membrane
fusion by interacting closely with a region of the protein
close to the fusion loop and thus stabilizing the post-fusion
‘hairpin’ conformation (reviewed by Harrison, 2008; Kielian
& Rey, 2006). Drummer & Poumbourios (2004) demon-
strated that conserved residues in the hydrophobic heptad
repeat were essential for HCV cell entry, and proposed that
this region of E2 is functionally homologous to the stem of
flavivirus E glycoproteins. The characteristics of mutant
in682 provide direct evidence that this region plays a role in
membrane fusion.
A tabulated summary of all the data obtained in this
analysis (Table 2) shows the relationships between the
fundamental properties of correct folding and hetero-
dimerization and the higher-level functions of receptor
binding, HCVpp incorporation, fusion and infectivity. Fig.
6 maps the insertions that affect specific functions on a
model of the E2 protein (Krey et al. 2010). Unfortunately,
the mutagenesis was relatively less informative about E1 in
that none of the E1 insertions that we obtained affected
heterodimer formation. However the insert at amino acid
position 324, which disrupts a very conserved region,
dramatically reduced incorporation of E1 into HCVpp. It is
striking that membrane fusion and HCVpp infectivity were
severely affected by all insertions in E1, except for one at
the very N terminus, thus emphasizing the involvement of
E1 in the fusion and entry process. The effects of insertions
within E2 point to the following structure–function
relationships: (i) correct folding of E2 requires the
structural integrity of regions 611–631 and 540–549; (ii)
E1E2 heterodimerization involves regions 587–597 and
692–727; (iii) CD81 binding is disrupted by insertions at
amino acid residues 422–425 and 531–534; (iv) incorp-
oration of E1E2 into HCVpp is reduced by insertions at
Fig. 6. Localization of insertions on the model of HCV E2. The
linear sequence of H77c E2 is represented as a chain of beads
threaded onto a class II fusion protein fold. Structural domains are
coloured red (DI), yellow (DII) and blue (DIII), the stem region is
grey and the unstructured regions (HVR1, HVR2 and IgVR) are
brown. Black font on bright colour indicates foreground residues
and white font on pale colour indicates background residues. The
transmembrane domain (TM) is represented by an ellipse at the C
terminus. Glycosylation sites are coloured green. CD81-binding
residues are circled in blue. Putative fusion-loop residues are
circled in red. Disulphide bonds are shown as black bars.
Intercalated stars show the position of insertions that retain
infectivity (white), and those that affect protein folding (yellow),
heterodimer formation (red), CD81 binding (blue) and fusion
(green). The amino acid residue immediately N-terminal to each
insertion is numbered. Adapted from Krey et al. (2010).
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fusion; and (v) insertion at Leu-682 specifically disrupts
fusion. Overall, our study shows that insertions at most
sites in the E1E2 glycoprotein complex abrogate infection.
A similar observation was made in the context of whole-
genome analysis, which showed that the E1E2 sequence is
considerably less tolerant of insertions than most other
regions of the HCV genome (Arumugaswami et al., 2008).
Nevertheless, we have identified positions in the E1
(aa 194) and E2 glycoproteins (aa 408 and 577, Fig. 6)
that can be modified by insertion of a short peptide
without loss of function. A small affinity tag inserted at
these positions could be used for purification of native
E1E2 heterodimer or even functional analysis of HCV
virions.
METHODS
Plasmid constructs. Plasmids encoding HCV genotype 1a strain
H77c E1E2 (aa 137–746 of the viral polyprotein; Yanagi et al., 1997),
the MLV Gag–Pol, and the MLV transfer vectors encoding GFP or
luciferase reporter have been described previously (Bartosch et al.,
2003a; Owsianka et al., 2005). The MLV transfer vector pCNC-TAT
(Ikeda et al., 2003) and the plasmid pLTR-luc were a kind gift from
Yasuhiro Takeuchi (University College London, UK) and Dan Littman
(New York University School of Medicine, USA), respectively.
Antibodies. Anti-E2 mAbs AP33, ALP98, H35, H48 and H53, anti-
E2 rabbit polyclonal serum R646, and anti-E1 mAbs A4 and AP21.010
have been described previously (Clayton et al., 2002; Cocquerel et al.,
1998, 2003; Dubuisson et al., 1994; Owsianka et al., 2001). Human
mAbs H-111 (anti-E1), and CBH-4B, CBH-4D, CBH-4G, CBH-5 and
CBH-7 (all anti-E2) have been reported previously (Hadlock et al.,
2000; Keck et al., 2004b). MLV capsid-specific mAb was obtained
from rat hybridoma cells (ATCC accession no. CRL-1912). Anti-b-
actin mAb was purchased from Santa Cruz Biotechnology.
Construction of mutants. Random mutations in HCV E1E2
glycoproteins were generated by linker-scanning mutagenesis using a
Tn-7-based transposon mutagenesis kit (GPS-LS Linker Scanning
System; NEB). In brief, the plasmid encoding HCV genotype 1a strain
H77 E1E2 cDNA was used as a target template in an in vitro
transposition reaction with a donor plasmid containing a kanamycin
selection marker flanked by two attachment sites (Tn7L and Tn7R) for
transposase. After transformation into Escherichia coli strain DH5-a,
plasmids from kanamycin-resistant colonies were screened by restric-
tion digestion to exclude insertions in the vector or promoter DNA.
Selected plasmids with insertions in the E1 and E2 gene sequences were
digested with PmeI, to remove most of the transposon containing the
selection marker, and self-ligated, resulting in 15-base-pair insertions.
The nucleotide sequence of the insertions was TGTTTAAACA(N)5,
where (N)5 are the duplicated nucleic acid residues of the target
sequence at the insertion site. All the mutants were sequenced to
identify the position and sequence of the insertions.
Cell lines. Human hepatoma Huh-7 cells and human epithelial
kidney HEK-293T cells were propagated as described previously by
Owsianka et al., (2005). Huh7-J6 indicator cells were generated by
transducing Huh-7 cells with HIV-1 Tat expression vector pCNC-
TAT and selecting in medium containing 500 mg G418 ml
21.
HCVpp infectivity and glycoprotein incorporation. HCVpp were
produced as described previously (Bartosch et al., 2003a). In brief,
HEK-293T cells were co-transfected with plasmids encoding WT or
mutated HCV E1E2 cDNA, the MLV Gag–Pol packaging vector and
the MLV–GFP or MLV–luc transfer vector. Control pseudoparticles
were generated by omitting the glycoprotein construct. At 2 days
post-transfection, the pseudoparticle-containing medium was har-
vested, clarified, filtered (0.45 mm pore size) and used to infect Huh-7
cells. After 4 h incubation at 37 uC, the inoculum was replaced with
fresh medium, the cells incubated for 4 days and then the cells were
analysed for reporter-gene expression by flow cytometry on a
FACSCalibur (GFP) or by using Bright-Glo (Promega) and a
Chameleon II plate reader (luciferase).
To analyse incorporation of mutated E1E2, HCVpps were concen-
trated and purified by ultracentrifugation over a 20% sucrose cushion
(116000 g, 3 h, 4 uC). The pellets were resuspended in PBS (pH 7.4)
to concentrate viral particles 20-fold and incubated with anti-E2 R646
rabbit antiserum for 2 h at 4 uC. Antibody complexes were
precipitated by using protein A–Sepharose (Sigma-Aldrich) and
analysed by SDS-PAGE (10% acrylamide gels) followed by immuno-
blotting with E1 (A4), E2 (AP33 and ALP98) and MLV-gag mAbs,
followed by HRP-conjugated anti-species secondary antibodies and
enhanced chemiluminescence detection (SuperSignal West Dura
Chemiluminescent Substrate; Thermo Scientific).
Analysis of heterodimer formation. HEK-293T cells were tran-
siently transfected with plasmids encoding WT or mutated HCV E1E2
cDNA. Mock-transfected cells served as a negative control. At 48 h
post-transfection, cells were incubated for 30 min with lysis buffer
(20 mM Tris/HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton
X-100, 20 mM iodoacetamide). Lysates were clarified by centrifu-
gation and incubated with anti-E2 R646 rabbit antiserum for 2 h at
4 uC. The antibody complexes were precipitated by using protein A–
Sepharose and analysed by SDS-PAGE and immunoblotting with E1
and E2 mAbs, as described above.
GNA ELISA. Detection of E1E2 by ELISA was performed as described
by Patel et al. (2000). Briefly, Immulon II plates coated with GNA
were used to capture glycoproteins from lysates of HEK-293T cells
transiently expressing WT or mutated E1E2, prepared as described
above. Lysate from mock-transfected cells served as a negative
control. Bound proteins were detected by using appropriate
antibodies followed by anti-species IgG–HRP conjugate and TMB
substrate (Sigma). Statistical analysis was carried out using a Z-test to
assess whether there was a significant difference between the reactivity
of each individual mutant and the mean of the whole dataset, the null
hypothesis being that all mutants were identical to WT.
CD81 binding assay. Microtitre plates (Costar 3590) coated with
0.5 mg human CD81–LEL–GST fusion protein ml
21 were used to
capture glycoproteins from lysates of HEK-293T cells transiently
expressing WT or mutated E1E2, prepared as described above. Lysate
concentrations were normalized for E2 reactivity with mAbs AP33
and ALP98 in GNA ELISAs. Lysate from mock-transfected cells served
as a negative control. The CD81-bound glycoproteins were detected
by using anti-E2 serum R646 and anti-rabbit IgG–HRP conjugate.
Statistical analysis was carried out as above.
HCV cell–cell fusion. The assay was performed essentially as
previously described (Kobayashi et al., 2006; Lavillette et al., 2007).
Briefly, HEK-293T cells were co-transfected with plasmids encoding
WT or mutated E1 and E2 glycoprotein sequences and HIV-2 LTR
luciferase reporter gene (pLTR-luc). Control cells were transfected
with (i) WT E1E2 but no reporter and (ii) empty phCMV vector and
pLTR-luc. After 12 h incubation at 37 uC, transfected cells were
reseeded at 10
5 cells per well in six-well plates, together with Huh7-J6
indicator cells or Huh-7 control cells at 4610
5 cells per well. After
24 h of co-cultivation, the cells were washed with PBS, incubated for
Comprehensive mutagenesis of HCV E1 and E2 glycoproteins
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citrate, 10 mM MES, 5 mM HEPES) and washed three times with
medium. Luciferase activity was measured 24 h later by using Bright-
Glo (Promega).
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